ENvue Medical develops medical technology for enteral care, with a commercial focus on real-time guided bedside feeding tube placement. Its ENvue Navigation Platform is an FDA 510(k)-cleared electromagnetic navigation system for adult use that provides visual guidance as clinicians place feeding tubes into the gastrointestinal tract.
Company news commonly covers hospital adoption, group purchasing and distribution agreements, commercialization updates, and product-line expansion for ENFit syringes and enteral supplies. Updates also include intellectual-property activity tied to feeding tube navigation and the company's surface acoustic wave platform, including acoustic therapeutic technologies such as PainShield and UroShield for pain, bacterial colonization, and biofilm-related applications.
ENvue Medical (FEED) received a Nasdaq Hearings Panel decision on September 15, 2026 denying its request for continued listing on The Nasdaq Capital Market.
Trading of the company’s common stock will be suspended from Nasdaq and is expected to begin on the OTC Markets under the same ticker, FEED, on September 16, 2026. ENvue states that the decision does not affect its business operations, products, customers, or ongoing commercial activities. The company remains focused on commercialization of its ENvue Navigation System and other technologies, and is evaluating all available procedures and alternatives under Nasdaq Listing Rules, including a further appeal.
ENvue Medical (FEED) has resumed U.S. commercial shipments of NanoVibronix PainShield and begun fulfilling open orders from Ultra Pain Products, its exclusive U.S. distribution partner. This follows completion of ENvue’s transition of NanoVibronix manufacturing from Israel to the United States. With U.S. production now operational, ENvue is restoring commercial supply, supporting distributors and aiming to rebuild growth in the NanoVibronix business.
ENvue Medical (FEED) will exhibit its ENvue™ Navigation Platform at the Vizient® Innovative Technology Exchange on September 24, 2026, in Las Vegas, Nevada. The platform is a minimally invasive electromagnetic navigation system designed for real-time guided bedside feeding tube placement.
The Exchange allows selected suppliers to demonstrate technologies to supply chain and clinical leaders from Vizient’s hospital clients. ENvue highlights that its system enables real-time confirmation of feeding tube placement without X-ray, and cites an independent study of 531 procedures reporting zero inadvertent lung placements, a 67% reduction in ventilator-associated pneumonia, and an estimated first-year hospital cost avoidance of over $1.5 million based on AHRQ benchmarks.
ENvue Medical (NASDAQ: FEED) has approved a 1-for-12 reverse stock split of its issued and outstanding common stock, expected to become effective on September 1, 2026. FEED will continue trading on the Nasdaq Capital Market under the same ticker, but with new CUSIP 63008J876.
According to ENvue Medical, every twelve pre-split shares will be combined into one post-split share, reducing outstanding common shares from 11,084,616 to approximately 923,718, while authorized common shares remain at 40,000,000. Fractional shares will be rounded up to the nearest whole share per stockholder, and equity awards and convertible securities will be proportionally adjusted.
ENvue Medical (NASDAQ: FEED) entered a multi-year exclusive distribution agreement with Peak Medical to commercialize its UroShield® device across the United Kingdom and Republic of Ireland.
The agreement runs through December 31, 2029 and includes increasing annual minimum purchase commitments, from 650 units in 2026 to 35,000 units in 2029. In aggregate, Peak Medical’s minimum purchase commitments total approximately £2.1 million (about $2.6 million) over the initial term. ENvue said the deal is intended to expand market access and support revenue growth for UroShield, part of its NanoVibronix acoustic-based therapeutic product line.
ENvue Medical (NASDAQ: FEED) entered a securities purchase agreement with an institutional investor for an equity line of credit (“ELOC”) providing up to $50 million in capital, forming an equity financing facility (the “Facility). The Facility is subject to specified terms, including receipt of stockholder approval.
According to ENvue, the Facility is intended to enhance financial flexibility, fund advancement of its next-generation medical technology platform, and support evaluation of selective strategic acquisitions and business development opportunities. The company’s near-term priorities include accelerating adoption of its ENvue feeding tube navigation system, expanding its installed hospital base, increasing recurring feeding tube revenue, advancing navigation, AI and automation technologies, improving operating efficiency and disciplined capital allocation, and evaluating accretive acquisitions that could broaden its product portfolio and market reach.
ENvue Medical (NASDAQ: FEED) has completed moving manufacturing of its NanoVibronix product line from Israel to the United States and consolidated its research and development operations in Tel Aviv, Israel. The company states these changes support its broader plan to reduce operating expenses and improve its cost structure.
According to ENvue Medical, domestic manufacturing is expected to enhance operational efficiency, reduce costs, streamline supply chain management, and improve operational oversight. The NanoVibronix line, including PainShield and UroShield, uses proprietary low-intensity surface acoustic wave technology for home or care settings.
ENvue Medical (NASDAQ: FEED) announced the deployment of an additional ENvue™ Navigation Platform at an existing major academic medical center in the Dallas-Fort Worth Metroplex. The hospital, which treats a high volume of hospitalized patients, is expanding use of the system as clinician adoption grows across care settings.
The ENvue platform delivers real-time bedside visualization for feeding tube placement using a minimally invasive electromagnetic navigation system that is FDA 510(k) cleared for adult use. According to ENvue Medical, strengthening its presence in the Dallas-Fort Worth healthcare market is an important element of its commercial strategy.
ENvue Medical (NASDAQ: FEED) appointed current director and internationally recognized health system leader Zeev Rotstein, M.D. as Chairman of the Board, succeeding David Johnson, who is leaving the board along with director Nino Pionati.
According to ENvue Medical, the company also added Zvi Joseph, Head of AI Governance, Risk & Compliance at Amdocs, and Lior Buchman, a finance executive who has executed more than $320 million in financings and M&A for venture-backed tech and medical device companies. The company highlights their combined clinical, AI governance and capital markets expertise as support for ENvue’s navigation and AI platforms.
ENvue Medical (NASDAQ:FEED) announced the first successful prototype demonstration of ENvue Drive, a robotic-assisted feeding tube automation tool built on its 510(k) FDA-cleared ENvue Navigation Platform.
The prototype integrates Ask Oscar AI navigation, real-time electromagnetic guidance, and robotic-assisted tube advancement for bedside enteral access under clinician supervision. ENvue Drive is an investigational prototype, not submitted to the FDA and not cleared or approved for clinical use.